Extranodal NK-T-cell lymphoma secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Extranodal NK-T-cell lymphoma}}
{{Extranodal NK-T-cell lymphoma}}
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{RG}}


==Overview==
==Overview==




Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include: [[Lactate dehydrogenase|LDH]] measurement., [[MLH1|MLH]]1, PDGFRA, [[Vascular endothelial growth factor|VEGF]], [[PD-L1]], PD-1, [[Cyclin D1]], [[p53]], [[Ki-67]]
Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include: [[Lactate dehydrogenase|LDH]] , [[MLH1|MLH]]1, PDGFRA, [[Vascular endothelial growth factor|VEGF]], [[PD-L1]], PD-1, [[Cyclin D1]], [[p53]], [[Ki-67]]


==Secondary Prevention==
==Secondary Prevention==
Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include:<ref name="ZengHuang2019">{{cite journal|last1=Zeng|first1=Linshu|last2=Huang|first2=Wenting|last3=Cao|first3=Zheng|last4=Zheng|first4=Bo|last5=Liu|first5=Xiuyun|last6=Guo|first6=Lei|last7=Feng|first7=Xiaoli|title=The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage|journal=Annals of Hematology|volume=98|issue=6|year=2019|pages=1467–1476|issn=0939-5555|doi=10.1007/s00277-019-03643-9}}</ref>
Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include:<ref name="ZengHuang2019">{{cite journal|last1=Zeng|first1=Linshu|last2=Huang|first2=Wenting|last3=Cao|first3=Zheng|last4=Zheng|first4=Bo|last5=Liu|first5=Xiuyun|last6=Guo|first6=Lei|last7=Feng|first7=Xiaoli|title=The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage|journal=Annals of Hematology|volume=98|issue=6|year=2019|pages=1467–1476|issn=0939-5555|doi=10.1007/s00277-019-03643-9}}</ref>


* [[Lactate dehydrogenase|LDH]] measurement.
* [[Lactate dehydrogenase|LDH]]  
* [[MLH1]]
* [[MLH1]]
* PDGFRA
* PDGFRA

Latest revision as of 13:14, 3 September 2019

Extranodal NK-T-cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Extranodal NK-T-cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Xray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Extranodal NK-T-cell lymphoma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Extranodal NK-T-cell lymphoma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Extranodal NK-T-cell lymphoma secondary prevention

CDC on Extranodal NK-T-cell lymphoma secondary prevention

Extranodal NK-T-cell lymphoma secondary prevention in the news

Blogs on Extranodal NK-T-cell lymphoma secondary prevention

Risk calculators and risk factors for Extranodal NK-T-cell lymphoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]

Overview

Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include: LDH , MLH1, PDGFRA, VEGF, PD-L1, PD-1, Cyclin D1, p53, Ki-67

Secondary Prevention

Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include:[1]

References

  1. Zeng, Linshu; Huang, Wenting; Cao, Zheng; Zheng, Bo; Liu, Xiuyun; Guo, Lei; Feng, Xiaoli (2019). "The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage". Annals of Hematology. 98 (6): 1467–1476. doi:10.1007/s00277-019-03643-9. ISSN 0939-5555.

Template:WH Template:WS